Navigation Links
NeoTract Designates Dr. Vi Hua as UroLift® Center of Excellence
Date:12/31/2019

NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced that Dr. Vi Hua MD Valley Urologic Associates in Goodyear, AZ has been designated as a UroLift® Center of Excellence. The designation recognizes that Dr. Hua has achieved a high level of training and experience with the UroLift® System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia (BPH), also known as enlarged prostate.

Recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines, the FDA-cleared Prostatic Urethral Lift procedure using the UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to BPH. The UroLift permanent implants, delivered during a transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue.

The UroLift Center of Excellence program is designed to highlight urologists who are committed to educating their patients on BPH and the UroLift System as a treatment option and consistently seek to deliver excellent patient outcomes and experiences.

“We are pleased to recognize Dr. Vi Hua as a UroLift Center of Excellence for his commitment to providing consistent care to BPH patients using the UroLift System treatment,” said Dave Amerson, president of the Teleflex Interventional Urology business unit. “This achievement has helped many patients experience durable, long-term relief from the burdensome symptoms of BPH while preserving sexual function*1,2.”

Over 40 million men in the United States are affected by BPH, a condition that occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems and can cause loss of productivity, depression and decreased quality of life.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction, and retrograde ejaculation.

About the UroLift® System

The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function*1,2. Patients also experienced a significant improvement in quality of life. Over 100,000 men have been treated with the UroLift System in the U.S. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The Prostatic Urethral Lift procedure using the UroLift System is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at http://www.UroLift.com.

About NeoTract | Teleflex Interventional Urology

A wholly owned subsidiary of Teleflex Incorporated, the Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function*1,2. Learn more at http://www.NeoTract.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit http://www.teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose

For Teleflex Incorporated:
Jake Elguicze, 610.948.2836
Treasurer and Vice President, Investor Relations

Media:
Nicole Osmer, 650.454.0504
nicole@healthandcommerce.com

*No instances of new, sustained erectile or ejaculatory dysfunction
1. Roehrborn, J Urology 2013 LIFT Study
2.McVary, J Sex Med 2016

MAC00968-01 Rev A

Read the full story at https://www.prweb.com/releases/neotract_designates_dr_vi_hua_as_urolift_center_of_excellence/prweb16805525.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related medicine technology :

1. NeoTract Designates Dr. Patrick P. Daily as UroLift® Center of Excellence
2. NeoTract Designates Dr. T. Casey McCullough as UroLift® Center of Excellence
3. NeoTract Designates Dr. Tony Nimeh as UroLift® Center of Excellence
4. NeoTract Designates Dr. Samuel Dakil as UroLift® Center of Excellence
5. NeoTract Designates Dr. Timothy Lesser as UroLift® Center of Excellence
6. NeoTract Designates Dr. Elizabeth Mobley as UroLift® Center of Excellence
7. NeoTract Designates Dr. Kalpesh Patel as UroLift® Center of Excellence
8. Caris Life Sciences Designates Fox Chase Cancer Center a Caris Center of Excellence in Precision Medicine
9. Caris Life Sciences Designates Virginia Cancer Specialists as a Caris Center of Excellence
10. Caris Life Sciences Designates MedStar Health a Caris Center of Excellence
11. FDA Designates MST-188 As An Orphan Drug For Treatment Of Acute Limb Ischemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2020)... ... July 02, 2020 , ... ... distributor, is pleased to announce its donation of more than $190,000 in personal ... of Health and Human Services. As extreme medical shortages continue to plague the ...
(Date:7/1/2020)... ... July 01, 2020 , ... ... treating cancer, today announced the formation of its Scientific Advisory Board with the ... medical, scientific, and strategic advice to support company development and introduction of its ...
(Date:6/28/2020)... YORK (PRWEB) , ... June 26, 2020 , ... ... June’s 'Lung Health' campaign. The campaign brings together patients, healthcare providers, advocates, and ... in diagnostics, prevention, and treatment for these devastating respiratory conditions. , ...
Breaking Medicine Technology:
(Date:6/28/2020)... ALEXANDRIA, Va. (PRWEB) , ... June 26, 2020 ... ... issued a call for participation in the revision and redesignation of the ANSI/APSP/ICC-7 ... Spas, Hot Tubs, and Catch Basins. PHTA is seeking member participation on the ...
(Date:6/28/2020)... TEMECULA, Calif. (PRWEB) , ... June 26, 2020 ... ... been tougher. Inland Detox, the Inland Empire’s premier residential addiction treatment center, proudly ... of services that now includes special preparation for recovery in a world affected ...
(Date:6/28/2020)... ... 27, 2020 , ... The FSHD Society announced the opening ... the organization’s history. The online conference takes the place of FSHD Connect, the ... year due to COVID-19. Nearly 300 individuals and families living with FSHD are ...
(Date:6/25/2020)... ... , ... Denials Management, Inc. has just published The Health Insurance Appeals Guide ... denials of mental health and substance use disorder (MH/SUD) treatment services. It was written ... explain the steps in the appeals process. Complimentary copies of the Guide can ...
(Date:6/24/2020)... ... June 24, 2020 , ... Dr. Katinka van der Merwe, the ... requested guest on the True Grit and Grace podcast. She explains her outside-the-box, holistic ... remission is possible. , After being diagnosed with CRPS about 10 years ago, ...
Breaking Medicine News(10 mins):